Houston Matters

Houston Methodist Studying Effects of Emerging Immunotherapy Drug

A study underway at Methodist Hospital compares the effects of an immunotherapy drug to a chemotherapy drug on certain lung cancer development. Lung cancer is the second most common malignancy in the United States. We learn more about the study from its principal investigator, Dr. Eric Bernicker, Thoracic Medical Oncologist with the Houston Methodist Cancer […]

A study underway at Methodist Hospital compares the effects of an immunotherapy drug to a chemotherapy drug on certain lung cancer development. Lung cancer is the second most common malignancy in the United States.

We learn more about the study from its principal investigator, Dr. Eric Bernicker, Thoracic Medical Oncologist with the Houston Methodist Cancer Center.

Share

Michael Hagerty

Michael Hagerty

Senior Producer, Houston Matters

Michael Hagerty is the senior producer for Houston Matters. He's spent more than 20 years in public radio and television and dabbled in minor league baseball, spending four seasons as the public address announcer for the Reno Aces, the Triple-A affiliate of the Arizona Diamondbacks.

More Information